Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32591-7 · Cited by 3,336

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

Palma, D. A., Olson, R. A., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C. J. A., Mulroy, L. A., Lock, M. I., Rodrigues, G., Yaremko, B., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32487-5 · Cited by 1,879

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Cohen, E. E. W., Soulières, D., Tourneau, C. L., Dinis, J., Licitra, L. F., Ahn, M., Soria, A., Machiels, J., Mach, N., Mehra, R., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31999-8 · Cited by 1,737

Using immunotherapy to boost the abscopal effect

Ngwa, W., Irabor, O. C., Schoenfeld, J. D., Hesser, J., Demaria, S., & Formenti, S. C. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.6 · Cited by 1,260

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer

Theelen, W. S. M. E., Peulen, H. M. U., Lalezari, F., van der Noort, V., de Vries, J. F., Aerts, J. G. J. V., Dumoulin, D. W., Bahce, I., Niemeijer, A.-L. N., de Langen, A. J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1478 · Cited by 1,020

Radiotherapy induces responses of lung cancer to CTLA-4 blockade

Formenti, S. C., Rudqvist, N.-P., Golden, E., Cooper, B., Wennerberg, E., Lhuillier, C., Vanpouille-Box, C., Friedman, K., Ferrari de Andrade, L., Wucherpfennig, K. W., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0232-2 · Cited by 928

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

Cohen, E. E. W., Bell, R. B., Bifulco, C. B., Burtness, B. A., Gillison, M. L., Harrington, K. J., Le, Q., Lee, N. Y., Leidner, R. S., Lewis, R. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0662-5 · Cited by 733

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Lee, N. Y., Ferris, R. L., Psyrri, A., Haddad, R. I., Tahara, M., Bourhis, J., Harrington, K., Chang, P. M.-H., Lin, J.-C., Razaq, M. A., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30737-3 · Cited by 661

Advances in cancer immunotherapy 2019 – latest trends

Krüger, S., Ilmer, M., Kobold, S., Cadilha, B. L., Endres, S., Ormanns, S., Schuebbe, G., Renz, B. W., D’Haese, J. G., Schlößer, H., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1266-0 · Cited by 564

Emerging evidence for adapting radiotherapy to immunotherapy

Galluzzi, L., Aryankalayil, M. J., Coleman, C. N., & Formenti, S. C. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00782-x · Cited by 389

Immunotherapy for head and neck cancer: Recent advances and future directions

Cramer, J. D., Burtness, B. A., & Ferris, R. L. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104460 · Cited by 316

Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?

Demaria, S., Guha, C., Schoenfeld, J. D., Morris, Z. S., Monjazeb, A. M., Sikora, A. G., Crittenden, M. R., Shiao, S. L., Khleif, S. N., Gupta, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002038 · Cited by 321

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

Schoenfeld, J. D., Giobbie‐Hurder, A., Ranasinghe, S., Kao, K. Z., Lako, A., Tsuji, J., Liu, Y., Brennick, R. C., Gentzler, R. D., Lee, C. B., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00658-6 · Cited by 251

Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors

Darragh, L. B., Gadwa, J., Pham, T., Court, B. V., Neupert, B., Olimpo, N. A., Nguyen, K. A., Nguyen, D., Knitz, M. W., Hoen, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34676-w · Cited by 248

Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer

Shiao, S. L., Gouin, K. H., Ing, N., Ho, A. Y., Basho, R. K., Shah, A. S., Mebane, R. H., Zitser, D., Martinez, A., Mevises, N.-Y., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.012 · Cited by 212

Radiotherapy, immunity, and immune checkpoint inhibitors

Lynch, C. M., Pitroda, S. P., & Weichselbaum, R. R. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00075-5 · Cited by 225

Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma

Leidner, R. S., Crittenden, M. R., Young, K. H., Xiao, H., Wu, Y., Couey, M., Patel, A., Cheng, A. C., Watters, A. L., Bifulco, C. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002485 · Cited by 199

Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium

Kroeze, S. G. C., Pavic, M., Stellamans, K., Lievens, Y. N., Becherini, C., Scorsetti, M., Alongi, F., Ricardi, U., Jereczek‐Fossa, B. A., Westhoff, P. G., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00752-5 · Cited by 192

The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances

Janopaul-Naylor, J. R., Shen, Y., Qian, D. C., & Buchwald, Z. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011061 · Cited by 181

Radiotherapy and immunotherapy: open questions and future strategies

Pointer, K. B., Pitroda, S. P., & Weichselbaum, R. R. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.003 · Cited by 157

Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial

Kim, S., Wuthrick, E. J., Blakaj, D. M., Eroglu, Z., Verschraegen, C. F., Thapa, R., Mills, M. N., Dibs, K. N., Liveringhouse, C. L., Russell, J. S., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01659-2 · Cited by 151

Radiation therapy-induced remodeling of the tumor immune microenvironment

Charpentier, M., Spada, S., Nest, S. J. V., & Demaria, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.003 · Cited by 149

Radiotherapy and immunology

Wang, L., Lynch, C. M., Pitroda, S. P., Piffkó, A., Yang, K., Huser, A. K., Liang, H. L., & Weichselbaum, R. R. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232101 · Cited by 139

Radiotherapy and the immune system: More than just immune suppression

Rückert, M., Flohr, A.-S., Hecht, M., & Gaipl, U. S. (2021) · Stem Cells · doi:10.1002/stem.3391 · Cited by 133

Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment

Zhu, S., Wang, Y., Tang, J., & Cao, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1074477 · Cited by 137

Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study

Masini, C., Iotti, C., Giorgi, U. D., Bellia, S. R., Buti, S., Salaroli, F., Zampiva, I., Mazzarotto, R., Mucciarini, C., Vitale, M. G., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.09.016 · Cited by 119

Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC)

Chen, I. M., Johansen, J. S., Theile, S., Hjaltelin, J. X., Novitski, S. I., Brunak, S., Hasselby, J. P., Willemoe, G. L., Lorentzen, T., Madsen, K. S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02511 · Cited by 118

Amplifying “eat me signal” by immunogenic cell death for potentiating cancer immunotherapy

Xi, Y., Chen, L., Wang, L., Yu, B., Shen, W., & Niu, X. (2023) · Immunological Reviews · doi:10.1111/imr.13251 · Cited by 111

Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance

Zhou, X., Ni, Y., Liang, X., Lin, Y., An, B., He, X., & Zhao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915094 · Cited by 111

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

Yilmaz, E., Ismaila, N., Bauman, J. E., Dabney, R. S., Gan, G. N., Jordan, R. C., Kaufman, M., Kirtane, K., McBride, S. M., Old, M. O., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.02328 · Cited by 108

YKT6 , as a potential predictor of prognosis and immunotherapy response for oral squamous cell carcinoma, is related to cell invasion, metastasis, and CD8+ T cell infiltration

Yang, Z., Yan, G., Zheng, L., Gu, W., Liu, F., Chen, W., Cui, X., Wang, Y., Yang, Y., Chen, X., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1938890 · Cited by 105

Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

Spaas, M., Sundahl, N., Krüse, V., Rottey, S., Maeseneer, D. J. D., Duprez, F., Lievens, Y. N., Surmont, V. F. M., Brochez, L., Reynders, D., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.2132 · Cited by 107

A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC

Darragh, L. B., Knitz, M. W., Hu, J., Clambey, E. T., Backus, J., Dumit, A., Samedi, V., Bubak, A. N., Greene, C. S., Waxweiler, T. V., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00450-6 · Cited by 106

High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial

Patel, R. R., He, K., Barsoumian, H. B., Chang, J. Y., Tang, C. Z., Verma, V., Comeaux, N. I., Chun, S. G., Gandhi, S. J., Truong, M. T., et al. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.06.037 · Cited by 105

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies

Ionna, F., Bossi, P., Guida, A., Alberti, A., Muto, P., Salzano, G., Ottaiano, A., Maglitto, F., Leopardo, D., Felice, M. D., et al. (2021) · Cancers · doi:10.3390/cancers13102371 · Cited by 98

The oligometastatic spectrum in the era of improved detection and modern systemic therapy

Katipally, R. R., Pitroda, S. P., Juloori, A., Chmura, S. J., & Weichselbaum, R. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00655-9 · Cited by 87

Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges

Qian, J. M., & Schoenfeld, J. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.608772 · Cited by 84

Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma

Manukian, G., Bar‐Ad, V., Lü, B., Argiris, A. E., & Johnson, J. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00122 · Cited by 83

Radiotherapy: Brightness and darkness in the era of immunotherapy

Zhai, D., An, D., Wan, C., & Yang, K. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101366 · Cited by 73

The abscopal effect in patients with cancer receiving immunotherapy

Nelson, B. E., Adashek, J. J., Lin, S. H., & Subbiah, V. (2023) · Med · doi:10.1016/j.medj.2023.02.003 · Cited by 69

CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks

Hovhannisyan, L., Riether, C., Aebersold, D. M., Medová, M., & Zimmer, Y. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01775-1 · Cited by 69

Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients

Chen, J., Levy, A., Tian, A.-L., Huang, X., Cai, G., Fidelle, M., Rauber, C., Ly, P., Pizzato, E., Sitterle, L., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.010 · Cited by 67

Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer

Huang, J. C., Theelen, W. S. M. E., Belcaid, Z., Najjar, M., van der Geest, D., Singh, D., Cherry, C., Balan, A., White, J. R., Wehr, J., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01018-w · Cited by 77

A Review of Ongoing Trials of Stereotactic Ablative Radiotherapy for Oligometastatic Cancers: Where Will the Evidence Lead?

Al-Shafa, F., Arifin, A. J., Rodrigues, G., Palma, D. A., & Louie, A. V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00543 · Cited by 65

Lighting up the tumor fire with low-dose irradiation

Herrera, F. G., Romero, P. J., & Coukos, G. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.01.006 · Cited by 68

Advancements of radiotherapy for recurrent head and neck cancer in modern era

Zhang, S., Zeng, N., Yang, J., He, J., Zhu, F., Liao, W., Xiong, M., & Li, Y. (2023) · Radiation Oncology · doi:10.1186/s13014-023-02342-0 · Cited by 62

Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors

Hauth, F., Ho, A. Y., Ferrone, S., & Duda, D. G. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.0168 · Cited by 62

Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade

Appleton, E. S., Hassan, J., Hak, C. C. W., Sivamanoharan, N., Wilkins, A. C., Samson, A., Ono, M., Harrington, K. J., Melcher, A. A., & Wennerberg, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.754436 · Cited by 63

Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges

Wise-Draper, T. M., Bahig, H., Tonneau, M., Karivedu, V., & Burtness, B. A. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_350442 · Cited by 60

Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns.

Sgouros, G., Dewaraja, Y. K., Escorcia, F. E., Graves, S. A., Hope, T. A., Iravani, A., Pandit-Taskar, N. D., Saboury, B., James, S. S., & ZANZONICO, P. B. (2021) · PubMed Central · doi:10.2967/jnumed.121.262750 · Cited by 54

PAI-1-driven SFRP2high cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapy

Zhang, Y.-P., Guo, Z.-Q., Cai, X.-T., Rong, Z.-X., Fang, Y., Chen, J., Zhuang, K., Ruan, M.-J., Ma, S.-C., Lin, L.-Y., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.024 · Cited by 58

Regulatory T Cells Shape the Differential Impact of Radiation Dose-Fractionation Schedules on Host Innate and Adaptive Antitumor Immune Defenses

Sia, J., Hagekyriakou, J., Chindris, I., Albarakati, H., Leong, T., Schlenker, R., Keam, S. P., Williams, S., Neeson, P. J., Johnstone, R. W., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.05.014 · Cited by 54

The abscopal effect: a sense of DNA damage is in the air

Lippert, T. P., & Greenberg, R. A. (2021) · Journal of Clinical Investigation · doi:10.1172/jci148274 · Cited by 53

Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors

Sadagopan, A., Michelakos, T. P., Boyiadzis, G., Ferrone, C. R., & Ferrone, S. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.5970 · Cited by 49

Oligometastases: Emerging Evidence

Liu, W., Bahig, H., & Palma, D. A. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01482 · Cited by 48

Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials

Poulose, J. V., & Kainickal, C. T. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i5.388 · Cited by 48

ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models

Jin, W. J., Zangl, L. M., Hyun, M., Massoud, E., Schroeder, K., Alexandridis, R. A., & Morris, Z. S. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007474 · Cited by 45

Metastasis-directed therapy for oligometastasis and beyond

Beckham, T. H., Yang, J. T., Gomez, D. R., & Tsai, C. J. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01128-5 · Cited by 46

A minimally designed PD-L1-targeted nanocomposite for positive feedback-based multimodal cancer therapy

Mei, Y., Tang, L., Zhang, L., Hu, J., Zhang, Z., He, S., Zang, J., & Wang, W. (2022) · Materials Today · doi:10.1016/j.mattod.2022.09.009 · Cited by 47

Mathematical Modeling to Simulate the Effect of Adding Radiation Therapy to Immunotherapy and Application to Hepatocellular Carcinoma

Sung, W., Hong, T. S., Poznansky, M. C., Paganetti, H., & Grassberger, C. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.11.008 · Cited by 46

Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis

Xu, Y., Zhu, G., Maroun, C. A., Wu, X., Huang, D., Seiwert, T. Y., Liu, Y., Mandal, R., & Zhang, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645170 · Cited by 46

Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Choudhury, A. D., Kwak, L., Cheung, A., Allaire, K. M., Marquez, J., Yang, D. D., Tripathi, A., Kilar, J. M., Flynn, M., Maynard, B., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0306 · Cited by 47

Imaging approaches and radiomics: toward a new era of ultraprecision radioimmunotherapy?

Sun, R., Henry, T., Laville, A., Carré, A., Hamaoui, A., Bockel, S., Chaffai, I., Lévy, A., Chargari, C., Robert, C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004848 · Cited by 47

Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation

Morris, Z. S., Demaria, S., Monjazeb, A. M., Formenti, S. C., Weichselbaum, R. R., Welsh, J. D., Enderling, H., Schoenfeld, J. D., Brody, J., McGee, H. M., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00656-9 · Cited by 49

Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies

Boustani, J., Lecoester, B., Baude, J., Latour, C., Adotévi, O., Mirjolet, C., & Truc, G. (2021) · Cancers · doi:10.3390/cancers13194893 · Cited by 44

Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non–Small Cell Lung Cancer Patients

Zhou, X., Zhou, L., Yao, Z., Huang, M., Gong, Y., Zou, B., Zhu, J., Liu, Y., Peng, F., Zhang, Y., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0315 · Cited by 43

Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy

Darragh, L. B., & Karam, S. D. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-025-00903-x · Cited by 49

Combining Radiotherapy and Immunotherapy in Head and Neck Cancer

Runnels, J., Bloom, J. R., Hsieh, K., Dickstein, D. R., Shi, Y., Jones, B. M., Lehrer, E. J., & Bakst, R. L. (2023) · Biomedicines · doi:10.3390/biomedicines11082097 · Cited by 40

Severe Lymphopenia During Chemoradiation Therapy for Esophageal Cancer: Comprehensive Analysis of Randomized Phase 2B Trial of Proton Beam Therapy Versus Intensity Modulated Radiation Therapy

Wang, X. W., van Rossum, P. S. N., Chu, Y., Hobbs, B. P., Grassberger, C., Hong, T. S., Liao, Z. X., Yang, J., Zhang, X., Netherton, T., et al. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.08.058 · Cited by 38

The Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific Perspectives

Wisdom, A. J., Barker, C. A., Chang, J. Y., Demaria, S., Formenti, S. C., Grassberger, C., Gregucci, F., Hoppe, B. S., Kirsch, D. G., Marciscano, A. E. E., et al. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.12.046 · Cited by 39

Gold-siRNA supraclusters enhance the anti-tumor immune response of stereotactic ablative radiotherapy at primary and metastatic tumors

Jiang, Y., Cao, H., Deng, H., Guan, L., Langthasa, J., Colburg, D. R. C., Melemenidis, S., Cotton, R. M., Aleman, J., Wang, X., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02448-0 · Cited by 39

Immunotherapeutic strategies in head and neck cancer: challenges and opportunities

Liu, X., Harbison, R. A., Varvares, M. A., Puram, S. V., & Peng, G. (2025) · Journal of Clinical Investigation · doi:10.1172/jci188128 · Cited by 38

Tumor-Specific Antibody, Cetuximab, Enhances the In Situ Vaccine Effect of Radiation in Immunologically Cold Head and Neck Squamous Cell Carcinoma

Jin, W. J., Erbe, A. K., Schwarz, C. N., Jaquish, A. A., Anderson, B. R., Sriramaneni, R. N., Jagodinsky, J. C., Bates, A. M., Clark, P. A., Le, T. Q. H., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.591139 · Cited by 41

Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy

Elbanna, M., Chowdhury, N. N., Rhome, R. M., & Fishel, M. L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.749496 · Cited by 44

Opportunities and challenges in combining immunotherapy and radiotherapy in head and neck cancers

Wong, K. C. W., Johnson, D., Hui, E. P., Lam, R. C. T., Ma, B. B. Y., & Chan, A. T. �. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102361 · Cited by 41

Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus

Turchan, W. T., Pitroda, S. P., & Weichselbaum, R. R. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0145 · Cited by 37

Synergizing radiotherapy and immunotherapy: Current challenges and strategies for optimization

Rajeev-Kumar, G., & Pitroda, S. P. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100867 · Cited by 39

Advances in Targeted Therapy for the Treatment of Cervical Cancer

Watkins, D., Craig, D. J., Vellani, S. D., Hegazi, A., Fredrickson, K. J., Walter, A., Stanbery, L., & Nemunaitis, J. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185992 · Cited by 40

Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation

Chang, V. A., Simpson, D. R., Daniels, G. A., & Piccioni, D. E. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0471-2 · Cited by 37

The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy

Chen, Y., Ding, X., Bai, X., Zhou, Z., Liu, Y., Zhang, X., Yu, J., & Hu, M. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110329 · Cited by 37

Time to Debunk an Urban Myth? The “Abscopal Effect” With Radiation and Anti–PD-1

Seiwert, T. Y., & Kiess, A. P. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02046 · Cited by 37

FLT3L release by NK cells enhances response to radioimmunotherapy in preclinical models of HNSCC

Bickett, T. E., Knitz, M. M., Darragh, L., Bhatia, S., Court, B. V., Gadwa, J., Bhuvane, S., Piper, M., Nguyen, D., Tu, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0971 · Cited by 26

Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas

dos Santos, L. V., Abrahão, C. M., & William, W. N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.596290 · Cited by 36

Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer

Jungles, K. M., Holcomb, E. A., Pearson, A. N., Jungles, K. R., Bishop, C. R., Pierce, L. J., Green, M. D., & Speers, C. W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1022542 · Cited by 36

Overcoming the Impact of Hypoxia in Driving Radiotherapy Resistance in Head and Neck Squamous Cell Carcinoma

Hill, R. M., Rocha, S., & Parsons, J. L. (2022) · Cancers · doi:10.3390/cancers14174130 · Cited by 33

Antitumor Immune Response Triggered by Metal-Based Photosensitizers for Photodynamic Therapy: Where Are We?

Jung, A. C., Moinard‐Butot, F., Thibaudeau, C., Gasser, G., & Gaiddon, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111788 · Cited by 33

Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists

Xing, D. T., Khor, R., Gan, H. K., Wada, M., Ermongkonchai, T., & Ng, S. P. (2021) · Cancers · doi:10.3390/cancers13225716 · Cited by 33

A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer

Lee, N. Y., Riaz, N., Wu, V., Brinkman, T., Tsai, C. J., Zhi, W., Fetten, J. V., Ho, A. L., Wong, R. J., Ghossein, R. A., et al. (2022) · Thyroid · doi:10.1089/thy.2022.0050 · Cited by 33

Oligometastatic Head and Neck Cancer: Challenges and Perspectives

Bahig, H., Huang, S. H., & O’Sullivan, B. (2022) · Cancers · doi:10.3390/cancers14163894 · Cited by 33

Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition

Daly, R. J., Scott, A. M., Klein, O., & Ernst, M. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01656-z · Cited by 35

The Evolving Interplay of SBRT and the Immune System, along with Future Directions in the Field

Miljanic, M., Montalvo, S. K., Aliru, M. L., Song, T., Leon-Camarena, M., Innella, K., Vujovic, D., Komaki, R. R., & Iyengar, P. (2022) · Cancers · doi:10.3390/cancers14184530 · Cited by 31

Tumor-Targeted Nonablative Radiation Promotes Solid Tumor CAR T-cell Therapy Efficacy

Quach, H. T., Skovgard, M. S., Villena‐Vargas, J., Bellis, R. Y., Chintala, N. K., Amador-Molina, A., Bai, Y., Banerjee, S., Saini, J. K., Xiong, Y., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0840 · Cited by 31

Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors

Wu, Y., Yi, M., Niu, M., Zhou, B., Mei, Q., & Wu, K. (2024) · 癌症：英文版 · doi:10.1002/cac2.12576 · Cited by 30

Treatment Strategies for Oligometastatic Breast Cancer

Nesbit, E. G., Donnelly, E. D., & Strauss, J. B. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00889-2 · Cited by 30

Safety and Tolerability of Metastasis-Directed Radiation Therapy in the Era of Evolving Systemic, Immune, and Targeted Therapies

Guimond, E., Tsai, C. J., Hosni, A., O'Kane, G. M., Yang, J. T., & Barry, A. S. (2022) · Advances in Radiation Oncology · doi:10.1016/j.adro.2022.101022 · Cited by 34

Overview of the synergistic use of radiotherapy and immunotherapy in cancer treatment: current challenges and scopes of improvement

Colciago, R. R., Fischetti, I., Giandini, C., Rocca, E. L., Tiziana Rancati, T., Mateo, A. R., Colombo, M. P., Lozza, L., Chiodoni, C., Jachetti, E., et al. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2173175 · Cited by 29

Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside

Meattini, I., Livi, L., Lorito, N., Becherini, C., Bacci, M., Visani, L., Fozza, A., Belgioia, L., Loi, M., Mangoni, M., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102417 · Cited by 30

Top Ten Lessons Learned from Trials in Oligometastatic Cancers

Tan, V. S., & Palma, D. A. (2022) · Cancer Research and Treatment · doi:10.4143/crt.2022.1460 · Cited by 30

Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial

Gong, H., Tian, S., Ding, H., Tao, L., Wang, L., Wang, J., Wang, T., Yuan, X., Heng, Y., Zhang, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49121-3 · Cited by 30

Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?

von der Grün, J., Rödel, F., Brandts, C., Fokas, E., Gückenberger, M., Rödel, C. M., & Balermpas, P. (2019) · Cancers · doi:10.3390/cancers11040472 · Cited by 28

Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?

Khalifa, J., Mazières, J., Gomez‐Roca, C., Ayyoub, M., & Moyal, E. C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.662236 · Cited by 32

Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!

Maio, M., Blank, C. U., Necchi, A., Giacomo, A. M. D., Ibrahim, R. A., Lahn, M., Fox, B. A., Bell, R. B., Tortora, G., & Eggermont, A. M. M. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.04.035 · Cited by 28

Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study

Bailly-Caillé, B., Kottler, D., Morello, R., Lecornu, M., Kao, W., Meyer, E., Dompmartin, A., & L'Orphelin, J. ‐. (2023) · Cancers · doi:10.3390/cancers15020495 · Cited by 28

Combination radiation and αPD-L1 enhance tumor control by stimulating CD8+ PD-1+ TCF-1+ T cells in the tumor-draining lymph node

Shen, Y., Connolly, E. C., Aiello, M., Zhou, C., Chappa, P., Song, H., Tippitak, P., Clark, T. Y., Cardenas, M. A., Prokhnevska, N., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58510-1 · Cited by 27

Challenges in Combining Immunotherapy with Radiotherapy in Recurrent/Metastatic Head and Neck Cancer

Plavc, G., Jesenko, T., Oražem, M., & Strojan, P. (2020) · Cancers · doi:10.3390/cancers12113197 · Cited by 27

A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC).

McBride, S. M., Sherman, E. J., Tsai, C. J., Baxi, S. S., Aghalar, J., Eng, J., Zhi, W. I., McFarland, D. C., Michel, L. S., Spielsinger, D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.6009 · Cited by 61

CAMRESBRT: Randomized Phase II Trial of Camrelizumab with Stereotactic Body Radiotherapy vs. Camrelizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Lei, Q., Wang, Y., Sui, J.-D., Luo, Q., Jin, F., Long, B., Shu, X., Li, S., Huang, L., Zhong, M., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.07.1302

The Abscopal Effect in Head-and-Neck Squamous Cell Carcinoma Treated with Radiotherapy and Nivolumab: A Case Report and Literature Review

Forner, D. W. A., Horwich, P., Trites, J. R. B., Hollenhorst, H., Bullock, M. J., & Lamond, N. W. D. (2020) · Current Oncology · doi:10.3747/co.27.6687 · Cited by 25

A randomized phase II study of chemoradiation (CRT) +/- nivolumab (Nivo) with sequential safety evaluations of Nivo +/- lirilumab (Liri) or ipilumumab (Ipi) concomitant with (C) RT in intermediate (IR) and high-risk (HR) head and neck squamous cell carcinoma (HNSCC) (RTOG 3504, NCT02764593).

Gillison, M. L., Ferris, R. L., Zhang, Q., Colevas, A. D., Mell, L. K., Kong, C. S., Jordan, R. C., Moore, K. L., Truong, M. T., Kirsch, C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.tps6097 · Cited by 4

Safety Evaluation of Nivolumab Concomitant With Platinum-Based Chemoradiation therapy for Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504

Gillison, M. L., Ferris, R. L., Zhang, Q., Colevas, A. D., Mell, L. K., Kirsch, C., Moore, K. L., Truong, M. T., Kong, C. S., Jordan, R., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.12.022 · Cited by 11